IHFB Cognacq Jay — Clinical Trial Site

19 Registered trials

8 Currently recruiting

Organisation

IHFB Cognacq Jay

Location

Levallois-Perret, France

Identifier

ORG-100017274

Address

4 Rue Kleber, 92300, France

Departments

Department of Medical Oncology
Medical Oncology
Oncologie
Oncology
Service d'Oncologie Radiotherapie
Service d’Oncologie Médicale
Urology

Clinical trials at this site (19)

Search interface

Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Pending

2025-524408-30-01 Metastatic hormone-sensitive prostate cancer 5
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting

2023-505660-11-00 Cholangiocarcinoma (LTT, 26.0) 5 2024-04-24
Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting

2024-510580-28-00 Middle or low locally advanced resectable rectal carcin 5 2019-06-05
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human… Ended

2024-517024-20-00 Metastatic colorectal cancer patients 9 2022-09-27
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in… Ended

2024-518069-89-00 Patients with solid cancers 4 2020-02-03
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
Neoadjuvant pembrolizumab with a watch-and-wait strategy for patients with mismatch repair-deficient or microsatellite instability-high (dMM… Halted

2023-509322-22-00 localized colon cancer 4 2025-11-26
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal car… Ended

2024-516005-23-00 metastatic squamous cell anal carcinoma 4 2024-08-22
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Metastatic Colorectal Cancer (mCRC) 4 2023-06-02
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect… Ended

2023-503797-21-00 Metastatic Colorectal Cancer 5 2022-08-10